chufangao/CTO huggingface dataset:
Clinical trial NCT03434353: Study to Evaluate the Safety and Antiviral Activity of Inarigivir Soproxil (Formerly: GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB)
Official title: A Phase 2, Randomized, Open-Label, Active-Controlled Study to Evaluate the Safety and Antiviral Activity of GS-9992 Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Chronic Hepatitis B (CHB) Subjects
Sponsor: Gilead Sciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study was terminated due to sponsor's decision to not pursue further development of inarigivir soproxil in chronic hepatitis B.
Enrollment: 123.0 (ACTUAL)
Number of arms: 5.0
Start date: 2018-02-28
Primary completion date: 2020-01-20
Completion date: 2021-01-26
Baseline population: The Safety Analysis Set included all participants who took at least 1 dose of any study drug.
Plan to share individual participant data: NO
Clinical trial NCT04327505: Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19
Official title: A Randomized, Controlled, Open Label, Multicentre Clinical Trial to Explore Safety and Efficacy of Hyperbaric Oxygen for Preventing ICU Admission, Morbidity and Mortality in Adult Patients With COVID-19
Acronym: COVID-19-HBO
Sponsor: Karolinska Institutet (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Futility, change of disease due to virus mutations and/or vaccination
Enrollment: 34.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-06-03
Primary completion date: 2022-06-30
Completion date: 2022-12-01
Plan to share individual participant data: YES
IPD sharing description: The full study protocol, statistical plan and consent form will be publicly available when results are published. Data will be available on patient level; data will be pseudonymized. The full dataset and statistical code will be available upon request.
IPD time frame: Starting after publication and for 36 months
IPD access criteria: A full description of the intended use of the data must be sent to the corresponding author for review and approval. Participant consent for data sharing is conditioned and new ethics approval may be required.
Clinical trial NCT03926156: RIvoraxaban in Mitral Stenosis
Official title: RIvoraxaban Safety and Efficacy in Patients With Mitral Stenosis
Acronym: RISE MS
Sponsor: Rajaie Cardiovascular Medical and Research Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: COVID-19 has impacted our study recruitment
Enrollment: 40.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-05-22
Primary completion date: 2021-05-22
Completion date: 2021-08-14
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03812562: Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection
Official title: Pilot Study of Nivolumab in Combination With Therasphere (Yttrium-90) for Treatment of Hepatocellular Carcinoma (HCC) With Intent for Resection
Sponsor: Northwestern University (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: Lack of funding
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-02-07
Primary completion date: 2023-10-19
Completion date: 2023-10-19
Clinical trial NCT02318082: Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic GVHD
Official title: A Phase I Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic Graft-versus-Host-Disease
Sponsor: Dana-Farber Cancer Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 21.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-02-28
Primary completion date: 2017-10-31
Completion date: 2020-04-22
Clinical trial NCT04643158: Efficacy and Safety of Inhaled AZD1402 Administered for Four Weeks in Adults With Asthma on Medium-to-High Dose Inhaled Corticosteroids
Official title: A Two-part Phase IIa Randomised, Double-blind, Placebo-controlled, Dose-ranging, Multi-centre Study to Assess Efficacy and Safety of Inhaled AZD1402 Administered as a Dry Powder for Four Weeks in Adults With Asthma on Medium-to-High Dose Inhaled Corticosteroids
Acronym: APATURA
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The decision was based on lung findings from a non-clinical 13-week Good Laboratory Practice (GLP) toxicology study, which are not a concern for the active clinical studies but do not support long-term use and progression to later-stage development.
Enrollment: 72.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-03-12
Primary completion date: 2023-07-20
Completion date: 2023-07-20
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.~All request will be evaluated as per the AZ disclosure commitment:~https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.~Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in a sponsor approved tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Clinical trial NCT05293236: ApTOLL for the Treatment of COVID-19
Official title: A Double Blind, Placebo-Controlled, Randomized, Phase Ib Clinical Study of ApTOLL for the Treatment of COVID-19
Sponsor: aptaTargets S.L. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Lack of patients due to reduced incidence in the COVID-19 infected population in Spain
Enrollment: 5.0 (ACTUAL)
Number of arms: 4.0
Start date: 2022-01-14
Primary completion date: 2022-12-31
Completion date: 2022-12-31
Plan to share individual participant data: UNDECIDED
IPD sharing description: We have not planned this point yet
Clinical trial NCT04335552: Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection
Official title: Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection
Sponsor: Duke University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Poor recruitment, strong evidence from larger trials of no therapeutic benefit
Enrollment: 11.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-04-17
Primary completion date: 2020-06-17
Completion date: 2020-06-26
Plan to share individual participant data: NO
Clinical trial NCT03196401: A Study of Durvalumab (Anti-PDL1) Plus Radiation Therapy for the Treatment of Solitary Bone Plasmacytoma
Official title: A Pilot Study to Evaluate for the Abscopal Effect of Durvalumab (Anti-PD-L1) in Combination With Definitive Radiation Therapy in Solitary Bone Plasmacytoma With Limited Clonal Bone Marrow Plasmacytosis
Sponsor: Memorial Sloan Kettering Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: FDA recommendation
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-07-27
Primary completion date: 2020-06-30
Completion date: 2020-06-30
Clinical trial NCT04000594: A Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO7234292 (RG6042) in CSF and Plasma, and Safety and Tolerability Following Intrathecal Administration in Patients With Huntington's Disease
Official title: An Open-Label Adaptive Multiple-Dose Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO7234292 in CSF and Plasma, and Safety and Tolerability Following Intrathecal Administration in Patients With Huntington's Disease
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 12.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-09-02
Primary completion date: 2022-01-18
Completion date: 2022-01-18
Plan to share individual participant data: NO
IPD sharing description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Clinical trial NCT05414734: Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Characteristics of HHT120 in Healthy Subjects
Official title: A Single and Multiple Assending Doses Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamic Characteristics and Food Effect After Administration of HHT120 Capsule in Healthy Subjects
Acronym: HHT120
Sponsor: Zhejiang Huahai Pharmaceutical Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Commercialization consideration. Without safety issues.
Enrollment: 0.0 (ACTUAL)
Number of arms: 6.0
Start date: 2022-07-01
Primary completion date: 2023-02-15
Completion date: 2023-03-01
Clinical trial NCT02980003: PrevenTion of Contrast-inducEd nephroAThy With urinE Alkalinization
Official title: PrevenTion of Contrast-inducEd nephroAThy With urinE Alkalinization: the TEATE Study
Acronym: TEATE
Sponsor: G. d'Annunzio University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 240.0 (ACTUAL)
Number of arms: 3.0
Start date: 2015-03-31
Primary completion date: 2020-10-30
Completion date: 2021-05-01
Plan to share individual participant data: NO
Clinical trial NCT04192513: Observer-Blinded Dose Escalating, Single Dose to Study Safety and Antimicrobial Efficacy of Gel vs. Placebo
Official title: A Randomized, Observer-Blinded, Vehicle Controlled, Single Dose, Dose Escalating, Single Application Within-patient Bilateral Comparison to Study the Safety and Antimicrobial Efficacy of DBI-001 Gel Vs. Placebo
Sponsor: DermBiont, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Covid-19 has shut the clinic indefinitely
Enrollment: 9.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-05-20
Primary completion date: 2020-06-30
Completion date: 2020-06-30
Plan to share individual participant data: NO
Clinical trial NCT04304781: Phase 1 In-vivo Biliary Study of KSP/QRH Heptapeptide Dimer
Official title: Phase 1 In-vivo Study of KSP/QRH Heptapeptide Dimer for Detection of Biliary Intra-epithelial Neoplasia
Sponsor: University of Michigan (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Terminated due to lack of dimer.
Enrollment: 12.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-09-22
Primary completion date: 2021-12-17
Completion date: 2021-12-17
Plan to share individual participant data: NO
Clinical trial NCT05116046: Continuation Study of Long-term Safety, Tolerability, Pharmacokinetics and Efficacy of Recifercept in Achondroplasia
Official title: A PHASE 2 OPEN LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF RECIFERCEPT IN CHILDREN WITH ACHONDROPLASIA
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study was terminated due to lack of efficacy at any of the tested doses on 18th November 2022. The decision to terminate the study is not related to a safety concern.
Enrollment: 35.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-12-24
Primary completion date: 2022-12-16
Completion date: 2023-03-30
Baseline population: Full Analysis Set (FAS) included all participants who received at least 1 dose of recifercept. Participants were analyzed according to the dose they actually received.
Limitations and caveats: Data was not collected for efficacy endpoints as study was terminated early based on sponsor discretion due to lack of efficacy at any of the tested doses. The decision to terminate the study was not related to a safety concern.
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT03190304: The Effect of Neprilysin (LCZ696) on Exercise Tolerance in Patients With Heart Failure
Official title: The Effect of NEPRIlysin (LCZ696) on EXercise TOLerance, Muscle Vasodilatation, Muscle Strength and Body Composition in Patients With Heart Failure - NEPRIExTol-HF Trial
Acronym: NEPRIExTol
Sponsor: University of Sao Paulo General Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 52.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-06-14
Primary completion date: 2020-09-14
Completion date: 2020-09-23
Plan to share individual participant data: NO
Clinical trial NCT05214196: The Efficacy of Oral Antiseptics Against COVID-19
Official title: The Effectiveness of Oral Antiseptics on the Intraoral Viral Load of SARS-CoV-2
Sponsor: Ataturk University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 75.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-09-01
Primary completion date: 2021-12-01
Completion date: 2021-12-07
Plan to share individual participant data: NO
Clinical trial NCT03323866: Mometasone vs Budesonide in CRS With Polyposis
Official title: Randomized Controled Double-blinded Study Comparing Mometasone Nasal Spray to Budesonide Irrigations in Patients With Chronic Rhinosinusitis With Nasal Polyposis
Sponsor: Université de Sherbrooke (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Difficulty with recruitment
Enrollment: 36.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-05-01
Primary completion date: 2022-05-01
Completion date: 2022-08-01
Clinical trial NCT01920061: A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
Official title: A PHASE 1B OPEN-LABEL THREE-ARM MULTI-CENTER STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF PF-05212384 (PI3K/MTOR INHIBITOR) IN COMBINATION WITH OTHER ANTI-TUMOR AGENTS
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 110.0 (ACTUAL)
Number of arms: 5.0
Start date: 2013-09-10
Primary completion date: 2020-01-08
Completion date: 2020-01-08
Baseline population: All enrolled participants who received at least one dose of study medication.
Plan to share individual participant data: NO
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT03761069: Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias
Official title: Phase 1B Study of PTC299 in Relapsed/Refractory Acute Leukemias
Sponsor: PTC Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor terminated the study.
Enrollment: 33.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-10-29
Primary completion date: 2021-12-28
Completion date: 2021-12-28
Clinical trial NCT04167137: Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants
Official title: A Phase 1, Open-label, Multicenter Study of SYNB1891 Administered by Intratumoral Injection to Patients With Advanced/Metastatic Solid Tumors and Lymphoma Alone and in Combination With Atezolizumab
Sponsor: Synlogic (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Business reasons
Enrollment: 32.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-12-12
Primary completion date: 2021-12-09
Completion date: 2021-12-09
Baseline population: All participants who were enrolled, allocated to treatment, and received at least 1 dose of investigational product.
Limitations and caveats: The study was terminated prematurely by the Sponsor prior to enrollment completion.
Plan to share individual participant data: NO
Clinical trial NCT01231516: A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults
Official title: A Randomized, Double-blind Study of the Safety and Efficacy of GSK1349572 50 mg Once Daily Versus Raltegravir 400 mg Twice Daily, Both Administered With an Investigator-selected Background Regimen Over 48 Weeks in HIV-1 Infected, Integrase Inhibitor-Naïve, Antiretroviral-Experienced Adults
Acronym: SAILING
Sponsor: ViiV Healthcare (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 724.0 (ACTUAL)
Number of arms: 2.0
Start date: 2010-10-26
Primary completion date: 2013-02-04
Completion date: 2021-02-02
Baseline population: Four participants from one closed site were removed from the ITT-E Population creating the modified ITT-E Population with 715 participants.
Plan to share individual participant data: YES
IPD sharing description: IPD for this study will be made available via the Clinical Study Data Request site.
IPD time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
IPD access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted when justified, for up to another 12 months.
Clinical trial NCT00911339: Mobilization of Endothelial Progenitor Cells Induced by Atorvastatin in Patients With Stable Coronary Artery Disease Treated With Anti-CD 34 Antibodies Coated Stents
Official title: Mobilization of Endothelial Progenitor Cells Induced by Atorvastatin in Patients With Stable Coronary Artery Disease Treated With Anti-CD 34 Antibodies Coated Stents
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: prematurely interrupted because of difficulty in enrolment of patients.
Enrollment: 13.0 (ACTUAL)
Number of arms: 2.0
Start date: 2009-01-31
Primary completion date: 2021-05-13
Completion date: 2021-05-13
Clinical trial NCT02374021: Treatments Against RA and Effect on FDG-PET/CT
Official title: Treatments Against RA and Effect on FDG-PET/CT (The TARGET Trial)
Acronym: TARGET
Sponsor: Brigham and Women's Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 159.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-07-31
Primary completion date: 2021-05-31
Completion date: 2021-05-31
Baseline population: Baseline Patient Characteristics of Patients Included in Final Analyses
Clinical trial NCT04780464: A 3 Arm Randomized Study on Health-related QoL of Elderly Patients With Advanced Soft Tissue Sarcoma
Official title: a 3 Arm Randomized Study on Health-related Quality of Life of Elderly Patients With Advanced Soft Tissue Sarcoma Undergoing Doxorubicin Alone Every Three Weeks or Doxorubicin Weekly or Cyclophosphamide Plus Predniso(lo)ne Treatment
Acronym: Tolerance
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC (NETWORK)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Withdrawal grant provider
Enrollment: 14.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-04-11
Primary completion date: 2023-09-22
Completion date: 2023-11-11
Clinical trial NCT02540993: Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease
Official title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Event-driven Phase 3 Study to Investigate the Safety and Efficacy of Finerenone, in Addition to Standard of Care, on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease
Acronym: FIDELIO-DKD
Sponsor: Bayer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 5734.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-09-17
Primary completion date: 2020-04-14
Completion date: 2020-04-14
Baseline population: Full analysis set (FAS): the FAS comprised all randomized participants (except those with critical GCP violations)
Clinical trial NCT02945813: SAKK 08/15 - PROMET - Salvage Radiotherapy +/- Metformin for Patients With Prostate Cancer After Prostatectomy
Official title: SAKK 08/15 - PROMET - Multicenter, Randomized Phase II Trial of Salvage Radiotherapy +/- Metformin for Patients With Prostate Cancer After Prostatectomy
Sponsor: Swiss Group for Clinical Cancer Research (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Trial was prematurely closed for accrual by the SAKK Board and the follow-up period shortened to one year after last RT fraction of the last patient
Enrollment: 112.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-10-24
Primary completion date: 2022-02-28
Completion date: 2022-02-28
Plan to share individual participant data: NO
Clinical trial NCT03292146: Effects of Denosumab on Bone Mineral Density in Women With Anorexia Nervosa: A Pilot Study
Official title: Effects of Denosumab on Bone Mineral Density, Markers of Bone Metabolism and Bone Microarchitecture in Women With Anorexia Nervosa: A Pilot Study
Sponsor: Massachusetts General Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 30.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-10-25
Primary completion date: 2021-07-22
Completion date: 2021-07-22
Baseline population: Women, age 20-60 years, with anorexia nervosa or atypical anorexia nervosa and BMD T-score \< -1.0
Plan to share individual participant data: NO
Clinical trial NCT03600623: Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
Official title: Neoadjuvant Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy (SBRT) for Patients With Locally Advanced Pancreatic Cancer
Sponsor: University of Alabama at Birmingham (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: PI left the institution; no further accruals
Enrollment: 25.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-09-25
Primary completion date: 2020-07-30
Completion date: 2020-07-31
Plan to share individual participant data: NO